Patents by Inventor Williamson Ziegler Bradford
Williamson Ziegler Bradford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8735345Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: GrantFiled: February 26, 2010Date of Patent: May 27, 2014Assignees: Hoffmann la Roche Inc., Pharmasset, Inc., Roche Palo Alto LLCInventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
-
Patent number: 8648098Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.Type: GrantFiled: December 15, 2011Date of Patent: February 11, 2014Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Patent number: 8609701Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.Type: GrantFiled: November 9, 2009Date of Patent: December 17, 2013Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Patent number: 8592462Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.Type: GrantFiled: December 6, 2011Date of Patent: November 26, 2013Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Patent number: 8318780Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.Type: GrantFiled: September 2, 2011Date of Patent: November 27, 2012Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Publication number: 20120128628Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: February 26, 2010Publication date: May 24, 2012Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
-
Patent number: 8084475Abstract: The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.Type: GrantFiled: January 8, 2010Date of Patent: December 27, 2011Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Patent number: 8048862Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: GrantFiled: April 14, 2009Date of Patent: November 1, 2011Assignee: InterMune, Inc.Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
-
Patent number: 8013002Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.Type: GrantFiled: March 16, 2011Date of Patent: September 6, 2011Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Patent number: 7910610Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.Type: GrantFiled: October 8, 2010Date of Patent: March 22, 2011Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Publication number: 20110059047Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: November 18, 2010Publication date: March 10, 2011Applicant: InterMune, Inc.Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
-
Patent number: 7816383Abstract: The present invention relates to methods involving avoiding adverse drug interactions with fluvoxamine and pirfenidone or other moderate to strong inhibitors of CYP enzymes.Type: GrantFiled: January 8, 2010Date of Patent: October 19, 2010Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Publication number: 20100221217Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.Type: ApplicationFiled: February 26, 2010Publication date: September 2, 2010Applicants: InterMune, Inc., Roche Palo Alto LLC, Pharmasset, Inc.Inventors: Steven B. Porter, Williamson Ziegler Bradford, Patrick F. Smith, Ellen S. Yetzer, Abel De La Rosa, Michael D. Rogers, William T. Symonds
-
Patent number: 7767700Abstract: The invention relates to methods for decreasing adverse events associated with pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy. The invention discloses an optimized dose escalation scheme that results in the patient having increased tolerance to adverse events associated with the administration of pirfenidone. The invention also discloses a starter pack that may be used in conjunction with the dose escalation scheme.Type: GrantFiled: December 18, 2007Date of Patent: August 3, 2010Assignee: Intermune, Inc.Inventor: Williamson Ziegler Bradford
-
Patent number: 7635707Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage. The methods also include administering pirfenidone at the full target dose with no reduction and administering permanently reduced doses of pirfenidone.Type: GrantFiled: September 3, 2009Date of Patent: December 22, 2009Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Publication number: 20090269305Abstract: The embodiments provide compounds of the general Formulae I, II, III, IV, V, VI, VII, and X, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.Type: ApplicationFiled: April 14, 2009Publication date: October 29, 2009Applicant: InterMune, Inc.Inventors: Scott D. Seiwert, Leonid Beigelman, Brad Buckman, Antitsa Dimitrova Stoycheva, Steven B. Porter, Williamson Ziegler Bradford, Vladimir Serebryany
-
Patent number: 7566729Abstract: Methods are provided for administering pirfenidone to a patient that has exhibited abnormal biomarkers of liver function in response to pirfenidone administration. The methods include administering to a patient pirfenidone at doses lower than the full target dosage for a time period, followed by administering to the patient pirfenidone at the full target dosage.Type: GrantFiled: April 22, 2009Date of Patent: July 28, 2009Assignee: Intermune, Inc.Inventors: Williamson Ziegler Bradford, Javier Szwarcberg
-
Publication number: 20080102056Abstract: The present invention provides a marketing system and methods for marketing a dosage form comprising interferon gamma (IFN-?) to a patient in need thereof, for the treatment of idiopathic pulmonary fibrosis (IPF). The present invention further provides a method for increasing patient compliance. The present invention further provides methods of treatment and dosage forms compatible for use in the marketing systems and methods of the invention.Type: ApplicationFiled: February 2, 2004Publication date: May 1, 2008Applicant: INTERMUNE, INC.Inventors: Williamson Ziegler Bradford, James Pennington, Stephen Rosenfield